cyrilzakka/clinical-trials huggingface dataset:
Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

The purpose of this study is to determine the concentration of omega-3 fatty acids in plasma, blood and abdominal fat before and after bariatric surgery to provide guidance for future studies.

The omega-3 fatty acids are essential for human growth, development and well-being. Numerous studies have shown that a relatively high intake of the omega-3 fatty acids are beneficial in brain and visual development, psychiatric disorders, rheumatic disorders, inflammatory responses and cardiovascular disease. As an example, low levels of tissue omega-3 fatty acids are associated with a markedly higher rate of death from cardiac causes compared to patients with relatively high concentrations of the omega-3 fatty acids. Obese patients often have an unhealthy dietary intake and evidence of increased inflammatory processes. After a gastric bypass patients will have decreased absorption of fats from the gastrointestinal tract and may become fatty acid deficient. While gastric bypass may decrease death from cardiovascular disease in morbidly obese patients, cardiovascular disease is still the most common cause of death after a gastric bypass. There are numerous nutritional deficiencies which occur after gastric bypass and many of these are well documented. However, there are no data concerning the plasma and tissue levels of omega-3 fatty acids in morbidly obese patients either before or after operation.

Eligibility Criteria:
Inclusion Criteria:

* Surgical group candidates must be undergoing surgery for morbid obesity, abdominoplasty or other abdominal operation.
* Must have adequate venous access.

Exclusion Criteria:

* Insufficient venous access
Association Between Cancer and Sarcoidosis

The purpose of this study is to develop a clinical dataset of sarcoidosis patients with a diagnosis of cancer who are categorized by date of birth, sex, race/ethnicity, clinical information, laboratory and imaging information, time of sarcoidosis onset, cancer type and treatment, time of cancer diagnosis, stage and grade.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Sarcoidosis following cancer
* Granulomatous reaction must be proven by pathology

Exclusion Criteria:

. Aged younger than 18 years old.
CoV-PICS: A Virtual Post-ICU Clinic

This is a pilot study to evaluate the feasibility of a COVID-19 virtual Post Intensive Care Syndrome (PICS) clinic (CoV-PICS). The findings from this study are the first steps in determining the feasibility and potential impact of a telehealth PICS clinic that is able to address the needs of patients with COVID-19 disease and potentially other patients that are unable to attend a brick and mortar clinic and require virtual care.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* COVID-19 diagnosis with a stay in the ICU.
* A home internet connection or smartphone access, along with the ability to use them
* Missouri resident

Exclusion Criteria:

* Severe cognitive deficits or dementia prior to hospitalization
* Long-term resident of a skilled nursing facility prior to admission
* Non-English speaking (will not have an interpreter available)
* Hospice or Comfort Care at discharge
* No plans to return to some degree of independent living at the time of discharge
* Pregnant at the time of discharge
* Prisoner at the time of discharge
* Blind
* Deaf
Forearm Tourniquet With Small Dose Intravenous Lidocaine

The safety and effectiveness of the "mini-dose" Bier block, a technique of i.v. regional anesthesia using low-dose lidocaine (1.5 mg/kg) without routine premedication, was evaluated in the emergency department treatment of pediatric upper extremity fractures and dislocations.

this study aimed at comparing IVRA with small dose lidocaine and forearm tourniquet with conventional IVRA with arm tourniquet and usual lidocaine dose

Eligibility Criteria:
Inclusion Criteria:

* ASA(American society of anesthesia) I, II , consent, forearm or arm surgery

Exclusion Criteria:

* ASA(American society of anesthesia) III or more, allergy, refusal
Echocardiography in Septic Shock

BACKGROUND: Echocardiography can provide evaluation of right or left ventricular dysfunction and volume status during resuscitation of patients with sepsis and septic shock and guide intravenous vasopressor and fluid therapy. While there are numerous echocardiographic studies regarding cardiac function and volume status in patients with established shock, there are none that describe these during the early resuscitation of septic shock.

The study objective is to correlate echocardiographic findings with clinical parameters and net fluid balance measured during the early resuscitation of critically ill patients with sepsis and septic shock.

Aim 1) correlate echocardiographic findings of cardiac function with physiologic markers in the early hours of resuscitation

Aim 2) correlate cardiac function and fluid status with clinical outcomes

Aim 3) evaluate the change in cardiac function over time in patients with sepsis and septic shock

Aim 4) evaluate long term clinical outcomes for patients with sepsis and septic shock.


Eligibility Criteria:
Inclusion Criteria:

- at least 13 years of age

SEPSIS PATIENTS:

Sepsis patients must have

1. Suspected or confirmed infection

   AND
2. Organ dysfunction as defined by a SOFA \>= 2 above baseline (if no baseline data available, SOFA assumed to be 0)

OR

SEPTIC SHOCK PATIENTS:

AFTER INFUSION OF 20ML/KG CRYSTALLOID OR EQUIVALENT, Septic shock patients must have

1. Suspected or confirmed infection

   AND
2. Lactate \> 2 mmol/L

   AND
3. Receiving vasopressors

   * Enrollment of patients should occur within 8 hours of meeting criteria for severe sepsis or septic shock if it is required that a research only TTE be performed in the 0-6 hours after ICU admission. If a clinical TTE is performed in this timeframe, patients may be enrolled up to 24 hours after ICU admission.

Exclusion Criteria:

None.
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism

Patients with HCV genotype 1 and IL28B CC Polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Serum Hepatitis C RNA \> 10,000IU/mL
* Hepatitis C virus genotype 1
* IL28B CC polymorphism

Exclusion Criteria:

* Previous treatment for chronic Hepatitis C
* clinical or biological evidence of acute hepatitis, including serum ALT or AST \> 300U/ml
* HIV antibody positive, hepatitis b surface antigen positive or known diagnosis of other chronic liver disease
* Contraindications to PR-based treatment:

  * Uncontrolled psychiatric illness
  * Active substance dependency
  * Known autoimmune disorder
  * Untreated thyroid disease
  * Uncontrolled seizure disorder
  * Pregnancy, lactation or inability to maintain contraception
  * Chronic kidney disease w/ estimated GFR\< 60
  * ANC\<1.5/nl, Hb\<12g/dl, or platelets\<75/nl
* Clinical or biochemical evidence of decompensated liver disease including:

  * History of encephalopathy
  * Ascites
  * Variceal bleeding
  * Bilirubin \> 3g/dl or INR \> 1.5
  * Life threatening disorder with expected median survival less than 5 years
  * Inability to comply with drug regimens or testing schedule required for study
Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital (RMH)

To document pre-diagnosis educational abilities, to document any change in educational achievements following treatment, to document educational support given within the statement process and to document the timing of support.

This will be a retrospective study. Cases will be identified by looking at the Royal Marsden Hospital (RMH) coding database. All the patients will have completed treatment for a brain tumour. The children all need to have started school before the diagnosis of their brain tumour so that we can look at easily defined educational assessments in this cohort. Children will be identified by looking at RMH coding of diagnosis and include children aged between 4 years and 18 years old (school age).

Eligibility Criteria:
Inclusion Criteria:

* patients/parental consent for RMH accessing educational information from them and their school
* patients with a primary brain tumour

Exclusion Criteria:

* children with secondary brain tumours
* children who have had treatment for a relapse of primary brain tumour
Nulliparous Women and Education and Counseling

This study investigates the effect of education and counseling on anxiety and depression in nullipar women.

Pregnancy is a special process in a woman's life in which physiological, social and psychological changes occur. In this process, most women experience anxiety and depression, which are an important global health problem.The fear of uncertainty experienced by women who will become mothers for the first time may cause them to experience more anxiety/depression. The aim of this study was to investigate the effect of education and counseling on anxiety and depression of women.

This randomized controlled study was conducted at state hospital in northern Turkey , Obstetrics and Gynecology polyclinic between January 2022 and March 2022. Volunteer women undergoing polyclinic have been included. Participants were randomly assigned to the intervention or the control group using a computer-generated list. A data collection form including socio-demographic and obstetric characteristics such as age, educational status, Hospital Anxiety Depression Scale (HADS) was used for each patient. After obtaining written informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) were applied to both groups by face to face interview. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed.The IBM SPSS (Statistical package for the Social Sciences) 23.0 package program was used to evaluate the data obtained in the study.

Eligibility Criteria:
Inclusion Criteria:

* A healthy pregnant woman over 18 years of age,
* without a diagnosed psychiatric disease,
* without mental disability and communication problems,
* at 28 weeks of gestation,
* nulliparous,
* without fetal anomaly,
* without risky pregnancy

Exclusion Criteria:

* A healthy pregnant woman under 18 years of age,
* with a diagnosed psychiatric disease,
* with mental disability and communication problems,
* under 28 weeks of gestation,
* multiparous,
* with fetal anomaly,
* with risky pregnancy
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG).

Safety will be monitored throughout the study.

The study consists of a blinded 8-week Primary Evaluation Period (PEP) and a blinded 26-week Extended Treatment Period (ETP). After completion of 34 weeks of treatment, participants will enter an Open-label Extension (OLE) Period for up to 1.5 years.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with MG at least 3 months (90 days) prior to the date of the Screening Visit. Confirmation of MG must be made via the following:

  1. Positive serologic test for anti AChR antibodies at the Screening Visit, and
  2. Abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation, or
  3. Positive response to an AChEI test (eg, edrophonium chloride test), or
  4. Improvement of signs or symptoms related to MG during treatment with an oral AChEI, as determined by the treating physician
* Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at the Screening Visit.
* MG-ADL total score must be ≥ 5 (with at least 50% of the score attributed to non-ocular elements) at the Screening Visit and at randomization (Day 1).
* Participants receiving treatment with protocol-specified immunosuppressive therapies, corticosteroids, or acetylcholinesterase inhibitors must have been receiving treatment and on a stable dose prior to the date of the Screening Visit, with no changes to the regimen expected during screening, the PEP, and/or the ETP.

Exclusion Criteria:

* Estimated glomerular filtration rate ≤ 30 milliliters/minute/1.73 squared meters during Screening calculated by Chronic Kidney Disease Epidemiology Collaboration.
* History of thymectomy, thymomectomy, or any other thymic surgery within 12 months prior to the Screening Visit.
* Any untreated thymic malignancy, carcinoma, or thymoma. Participants with a history of treated thymic malignancy or carcinoma are eligible for enrollment if they meet pre-specified conditions outlined in the protocol.
* Clinical features consistent with Clinical Deterioration at the time of the Screening Visit or at any time during the Screening Period prior to randomization (Day 1).
* Use of the following within the time periods specified below:

  1. Intravenous immunoglobulin G or subcutaneous immunoglobulin within the 4 weeks (28 days) prior to the Screening Visit.
  2. Use of tacrolimus or cyclosporine within the 4 weeks (28 days) prior to the Screening Visit.
Primary Immunodeficiencies and Obstetrical Neuraxial Anaesthesia

The purpose of this study is to evaluate if neuraxial anesthesia (epidural or intradural anesthesia) used during childbirth is associated with more frequent infectious complications in patients with primary immunodeficiencies (PID).

Neuraxial anaesthesia (epidural or intradural) is often used to alleviate pain during labour and childbirth. Although extremely efficient and safe, rare but serious infectious complications such as epidural abscess or meningitis can occur afterwards.

Patients with PID tend to have a greater risk of infectious complications than the general population. With the progress of medical care in those pathologies, female patients are now giving birth more often. The use of neuraxial anaesthesia and the associated infectious complications have never been studied in this population.

The investigators intend to review the medical records of PID patients who gave birth in an APHP hospital in the last 10 years to evaluate the use of neuraxial anesthesia and the frequency of infectious complications associated with neuraxial anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* Female patient included in the CEREDIH national register
* Aged \> 18 years

Exclusion Criteria:

* Refuse to participate
* Deceased
* Minor
* under judicial protection
* obstetric file not available
Body Composition Reference Data for Preterm Infants

The American Academy of Pediatrics has recommended that growth in size (weight, length, and head circumference) and in body composition (fat and lean mass) in preterm infants should adhere as close as possible to the growth and body composition of a healthy infant in utero at the same gestational age. However, there are no body composition reference curves available at this time for the preterm infant population. The purpose of this study is to collect cross-sectional body composition data using air displacement plethysmography (PEA POD Infant Body Composition System, Life Measurement, Inc) on approximately 240 preterm infants within 3 days of birth, for the purpose of generating means, standard deviations, and percentile values for total body fat mass, total fat free mass, and percent body fat for infants born at 30-36 weeks gestation. Relatively healthy infants without evidence of growth retardation will be selected for form the reference sample. The goal is to generate a set of common reference curves to be used in clinical centers against which to compare body composition status for individual infants.


Eligibility Criteria:
Inclusion Criteria:

* Appropriate for gestational age (AGA), singleton, 30+0 and 36+6 weeks gestational age

Exclusion Criteria:

* Congenital defects that affect growth
* Inability to tolerate room air for 5 minutes without desaturation or bradycardia
* \<1 kg birth weight
* Parents did not provide consent
Brain Ultrasound in the Weaning of External Ventricular Leads

External Ventricular Deviation (EDV) is a medical device that provides transient and controlled external drainage of cerebrospinal fluid (CSF). This device can also monitor intracranial pressure (ICP). SEV is an emergency measure indicated for acute hydrocephalus and / or intracranial hypertension (HTIC). Weaning from a DVE should be considered as soon as possible from the moment the patient's clinical condition allows it. There is no consensus on how to wean SEVs.

The main objective of this study is to evaluate inter and intraobserver reproducibility of the measurement of the 3rd ventricle size by ultrasound in patients receiving a DVE withdrawal test.

Ultrasound assessment of the ventricular system, including the size of the 3rd ventricle, can be used in severe traumatic brain injury. Ultrasound measurement of the size of the 3rd ventricle is used as a marker to monitor cerebral atrophy in neurodegenerative diseases such as multiple sclerosis (MS). There is good correlation between brain ultrasound and MRI and CT brain imaging to assess the size of the 3rd ventricle. Ultrasound measurement of the size of the 3rd ventricle has never been evaluated in weaning external ventricular leads.

Measuring the size of the 3rd ventricle by ultrasound could be an interesting monitoring technique during a SEV withdrawal trial to predict success or failure.

Weaning is usually based on a clamp test with more or less paraclinical clinical monitoring. The recurrence of hydrocephalus and / or HTIC defines a withdrawal failure of the drainage device.

The size of the 3rd ventricle evaluated by cerebral CT in a clamp test is found as a predictor of weaning failure of a DVE.

Eligibility Criteria:
Inclusion Criteria:

* Patient benefiting from a DVE, whatever the indication
* Hospitalized in the neurosurgical resuscitation and neurosurgical intensive care units of Toulouse University Hospital
* First DVE withdrawal test initiated by the doctor in charge of the patient
* Major patient
* Affiliated person or beneficiary of a social security scheme.
* Expression of non-opposition by the participant or his / her confidant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion Criteria:

* Absence of cerebral acoustic window
* Patient with a ventriculoperitoneal (DVP) diversion before the DVE.
* Antecedent surgery in the cerebral ventricular system.
* Pregnant and lactating woman
* Person under safeguard of justice
* Nosocomial neuro-meningeal infection on untreated or treatment-emergent DVE
Correlation Between Headaches and Septum and Nasal Mucosa Contact

Headache is the most common complaint to neurologists. In the 80´s and 90's few papers, with limited number of patients, have proposed the association between nasal septum contact and headache. The International Classification of Headaches Disorders proposed specific diagnostic criteria for this entity.

With the major use of CT scans, the contact between nasal mucosa and septum is daily observed in many patients without complaint of headache.

The purpose of this study is to determine if there is any correlation between nasal and septum mucosa contact and the prevalence of headache. The investigators hypothesized that no correlation will be found using CT scans in a large series of patients.

Every patient older than 18 years old whom underwent sinuses or facial computed tomography will be asked to answer a questionnaire, where he will be able to describe his headache features (if present) . This information will be correlated with patient images findings, which are going to be evaluated by head and neck radiologists blinded for clinical information. Logistic regression model will be used to verify this association; the presence of sinusitis and fever will used be as covariates.

Eligibility Criteria:
Inclusion Criteria:

* All patients older than 18 years whom underwent sinuses or facial tomography.

Exclusion Criteria:

* Patients with clinical history of trauma
Outcome of Patients Undiagnosed Under Medical Thoracoscopy

Medical thoracoscopy (MT) under local anaesthetic and mild sedation, an established method in the diagnosis of pleural diseases. MT has an overall diagnostic yield above 90% for malignant pleural diseases and pleural tuberculosis. However, others who are diagnosed as fibrinous pleuritis make confusion in clinicians. Whether these patients are firmly followed or not ? The investigators do not know the answer of this question.

In this study the investigators aimed to investigate the outcome of the patients who are diagnosed as fibrinous pleuritis on MT biopsies.

Medical thoracoscopy (MT) under local anaesthetic and mild sedation, an established method in the diagnosis of pleural diseases with a sensitivity above 90% and specificity of 1000% for malignant pleural diseases and pleural tuberculosis. Except these two groups of patients, in others pleural histopathological diagnosis is defined as "non-specific pleuritis" or "fibrinous pleuritis". Authors say that the natural evolution of these patients is poorly understood. Some of these patients was later established false negative cases for malignant pleural diseases. Clinical guidelines recommend close observation of patients with undiagnosed exudative effusions, although the length and follow-up regime is not defined, yet. In this study the investigators examine the outcome of patients who are diagnosed as fibrinous pleuritis by MT.

Eligibility Criteria:
Inclusion Criteria:

* Undiagnosed exudative pleural effusion
* Under 20 years-old, over 85 years-old
* Followed 2 years at least

Exclusion Criteria:

* Transudative pleural effusion
* Patients who do not accepted medical thoracoscopy.
Measuring Cardiovascular Stress in Patients on Hemodialysis

To determine if proprietary software that uses pulse-wave analysis to interpret the output of a conventional pulse-oximeter, can predict the onset of circulatory stress, before changes in blood pressure and pulse occur, in patients undergoing outpatient hemodialysis.


Eligibility Criteria:
Inclusion Criteria:

* Patients having regular outpatient dialysis treatments
* Patients who are willing and able to provide informed consent

Exclusion Criteria:

* Patients who do not wish to participate
* Patients with contraindications to attachment of monitoring devices
* Patients with skin rash or hypersensitivity to the adhesive sensors